Patents Assigned to Bayer Healthcare AG
  • Patent number: 6936609
    Abstract: The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: August 30, 2005
    Assignee: Bayer HealthCare AG
    Inventors: Jens-Kerim Ergüden, Marcus Bauser, Nils Burkhardt, Dietmar Flubacher, Arno Friedl, Irene Gerlach, Volker Hinz, Reinhard Jork, Paul Naab, Maria Theresia Niewöhner, Thorsten Oliver Repp, Karl-Heinz Schlemmer, Jürgen Stoltefuss, David Brückner, Martin Hendrix, Dagmar Schauss, Adrian Tersteegen, Ulrich Niewöhner
  • Publication number: 20050182055
    Abstract: The present invention relates to a process for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide starting from 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)-dione, 4-(4-aminophenyl)-3-morpholinone and 5-chlorothiophene-2-carbonyl chloride.
    Type: Application
    Filed: January 10, 2005
    Publication date: August 18, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Mathias Berwe, Christian Thomas, Joachim Rehse, Dirk Grotjohann
  • Patent number: 6930108
    Abstract: The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the production of medicaments for the treatment of cardiac insufficiency, psoriasis, female infertility, cancer, diabetes, ophthalmic disorders such as glaucoma, disorders of gastric motility, cystic fibrosis, premature labour, pulmonary hypertension, bladder disorders, prostate hyperplasia, nitrate-induced tolerance, pre-eclampsia, alopecia, Parkinson's disease, pain, tinnitus or the renal syndrome.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: August 16, 2005
    Assignee: Bayer HealthCare AG
    Inventors: Maria Theresia Niewöhner, Erwin Bischoff, Helmut Haning, Afssaneh Rahbar, Tiemo-Joerg Bandel, Wolfgang Barth, Ulrich Niewöhner
  • Publication number: 20050176010
    Abstract: Reagents which regulate human transient receptor potential channel and reagents which bind to human transient receptor potential channel gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, urinary incontinence, overactive bladder, benign prostatic hyperplasia, lower urinary tract syndromes, and CNS disorders.
    Type: Application
    Filed: April 10, 2003
    Publication date: August 11, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Masahiro Shiroo, Noriyuki Yamamoto, Fumihiko Hayashi, Johannes Floeckner, Peter Reinemer, Jeffrey Encinas, Shinichi Watanabe, Masaomi Tajimi, Toshio Kokubo
  • Publication number: 20050164305
    Abstract: The invention provides a human FPRL1 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of FPRL1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 21, 2003
    Publication date: July 28, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20050159431
    Abstract: The invention relates to novel compounds of formula (I), to a method for the production thereof, and to their use as medicament active ingredients for the prophylaxis and/or treatment of diseases.
    Type: Application
    Filed: January 3, 2003
    Publication date: July 21, 2005
    Applicant: Bayer Healthcare AG
    Inventors: Barbara Albrecht, Michael Gerisch, Michael Harter, Thomas Krahn, Felix Oehme, Karl-Heinz Schlemmer, Henning Steinhagen
  • Patent number: 6919360
    Abstract: The present invention relates to chromans, to processes for their preparation and to their use in medicaments, in particular as agents for treating disorders of the central nervous system.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: July 19, 2005
    Assignee: Bayer HealthCare AG
    Inventors: Dietrich Scherling, Wolfgang Karl, Dietrich Seidel, Corinna Weinz, Rudolf Schohe-Loop, Frank Mauler
  • Publication number: 20050154230
    Abstract: This invention relates to urea derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The urea derivatives of the present invention has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.
    Type: Application
    Filed: December 13, 2002
    Publication date: July 14, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Takeshi Yura, Muneto Mogi, Yuka Ikegami, Tsutomu Masuda, Toshio Kokubo, Klaus Urbahns, Nagahiro Yoshida, Makiko Marumo, Masahiro Shiroo, Masaomi Tajimi, Keisuke Takeshita, Toshiya Moriwaki, Yasuhiro Tsukimi
  • Publication number: 20050154045
    Abstract: The invention relates to novel 1-aza-bicyclic N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Application
    Filed: March 3, 2003
    Publication date: July 14, 2005
    Applicant: Bayer Healthcare AG
    Inventors: Joachim Luithle, Frank-Gerhard Boss, Christiana Erb, Katrin Schnizler, Timo Flessner, Marja Kampen, Christoph Methfessel, Frank-Thorsten Hafner
  • Publication number: 20050130138
    Abstract: Disclosed are novel nucleic acid and amino acid sequences of immune-related proteins. Reagents that bind to immune-related gene products can be used to treat conditions involving inflammatory processes, such as allergy, asthma, autoimmune diseases, and other chronic inflammatory diseases where an over-activation or prolongation of the activation of the immune system causes damage to tissues.
    Type: Application
    Filed: May 10, 2002
    Publication date: June 16, 2005
    Applicant: Bayer HealthCare AG
    Inventor: Jeffrey Encinas
  • Publication number: 20050123919
    Abstract: The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.
    Type: Application
    Filed: February 14, 2003
    Publication date: June 9, 2005
    Applicant: Bayer Healthcare AG
    Inventors: Udo Stropp, Stephan Schwers, Harald Kallabis
  • Patent number: 6890922
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: May 10, 2005
    Assignee: Bayer Healthcare AG
    Inventors: Maria Niewohner, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Serno, Marc Nowakowski, Ulrich Niewöhner
  • Publication number: 20050080129
    Abstract: The invention relates to compounds of general formula (I), to a method for the production thereof, to pharmaceutical compositions containing them, and to their use in the treatment and/or prophlaxis of diseases in humans or animals, diseases. The compounds are derivatives of the natural substances andrimide and moiramide B.
    Type: Application
    Filed: November 7, 2002
    Publication date: April 14, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Shiffer, Mitsuyuki Shimada
  • Publication number: 20050075281
    Abstract: The invention relates to nonadepsipeptides and process for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
    Type: Application
    Filed: May 6, 2004
    Publication date: April 7, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Franz Von Nussbaum, Nina Brunner, Sonja Anlauf, Rainer Endermann, Chantal Furstner, Elke Hartmann, Johannes Kobberling, Jacques Ragot, Guido Schiffer, Joachim Schuhmacher, Niels Svenstrup, Joachim Telser, Michael-Alexander Bruning
  • Publication number: 20050070582
    Abstract: The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.
    Type: Application
    Filed: September 4, 2002
    Publication date: March 31, 2005
    Applicant: Bayer Healthcare AG
    Inventors: Yingfu Li, Akihiko Watanabe, Timothy Lowinger, Kevin Bacon, Norihiro Kawamura, Takuya Shintani, Tetsuo Kikuchi, Toshiya Moriwaki, Klaus Urbahns, Keiko Fukushima, Noriko Nunami, Takashi Yoshino, Toshiki Murata, Megumi Yamauchi, Hiroko Yoshino
  • Publication number: 20050065160
    Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
    Type: Application
    Filed: April 26, 2004
    Publication date: March 24, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Tobias Wunberg, Judith Baumeister, Ulrich Betz, Mario Jeske, Thomas Lampe, Susanne Nikolic, Jurgen Reefschlager, Rudolf Schohe-Loop, Frank Sussmeier, Holger Zimmermann, Rolf Grosser, Kerstin Henninger, Guy Hewlett, Jorg Keldenich, Dieter Lang, Peter Nell
  • Publication number: 20050049240
    Abstract: The invention relates to novel tetrahydroisoquinolines, to processes for their preparation and to their use for producing pharmaceuticals for the treatment and/or prophylaxis of diseases, in particular of states of pain.
    Type: Application
    Filed: September 11, 2002
    Publication date: March 3, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Nils Gribenow, Bernd Kalthof, Heinrich Meier, Stephan-Nicholas Wirtz, Peter Spreyer
  • Publication number: 20050037423
    Abstract: The invention concerns isotopically coded marker (ICAT) for mass spectrometric analysis of proteins, and the preparation and use of said markers.
    Type: Application
    Filed: October 30, 2002
    Publication date: February 17, 2005
    Applicant: Bayer Healthcare AG
    Inventors: Hans-Georg Lerchen, Oswald Lockhoff, Dorian Immler, Hans-Ulrich Siegmund
  • Patent number: 6833364
    Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which the substituents R1, R2, R3, A, X and Y are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: December 21, 2004
    Assignee: Bayer HealthCare AG
    Inventors: Alexander Straub, Achim Feurer, Cristina Alonso-Alija, Elke Stahl, Johannes-Peter Stasch, Elisabeth Perzborn, Joachim Hütter, Klaus Dembowsky
  • Publication number: 20040254194
    Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.
    Type: Application
    Filed: February 10, 2004
    Publication date: December 16, 2004
    Applicant: Bayer HealthCare AG
    Inventors: Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton